ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Stendra: Auxilium Gets The Rights for New ED pill
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 1057" data-attributes="member: 3"><p>[ATTACH]242[/ATTACH]</p><p></p><p></p><p>Stendra (Avanafil) is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA (Europe) on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. Auxilium (makers of the testosterone gel Testim) just gained rights to that drug.</p><p></p><p>The manufacturer claims Stendra works in 15 minutes. The side effects seems to be similar to those of Viagra (sinus stuffiness, facial flushing, etc)</p><p></p><p>It is estimated that more than 50 percent of men over 40 years of age experience some degree of ED[1]. Prevalence of the condition increases with age and can be caused by a variety of factors, including medications (anti-hypertensives, histamine receptor antagonists); lifestyle (tobacco, alcohol use); diseases (diabetes, cardiovascular conditions, prostate cancer); prostatectomy, and spinal cord injuries. The market opportunity for ED medical treatments continues to grow, with U.S. sales exceeding $2.9 billion in 2012[2]. About one half of men being treated with currently available PDE5 inhibitors are dissatisfied with the results of that treatment and tend to switch among the products in pursuit of better efficacy or less side effects[3].</p><p></p><p>[1] Andre B. Prevalence and Incidence of Androgen Deficiency in Middle-Aged and Older Men: Estimates from The Massachusetts Male Ageing Study. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(12):5920-5926.</p><p>[2] US TRx revenues per Symphony Health</p><p>[3] Impact CR Consumer Segmentation, Feb. 2013; Qualitative Market Interviews (n= 722); HCP Research, Primary Interviews, Life Science Strategy Group LLC n= 64, June 2010.</p><p></p><p><a href="http://online.wsj.com/article/PR-CO-20131011-905164.html" target="_blank">http://online.wsj.com/article/PR-CO-20131011-905164.html</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 1057, member: 3"] [ATTACH=CONFIG]242[/ATTACH] Stendra (Avanafil) is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA (Europe) on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. Auxilium (makers of the testosterone gel Testim) just gained rights to that drug. The manufacturer claims Stendra works in 15 minutes. The side effects seems to be similar to those of Viagra (sinus stuffiness, facial flushing, etc) It is estimated that more than 50 percent of men over 40 years of age experience some degree of ED[1]. Prevalence of the condition increases with age and can be caused by a variety of factors, including medications (anti-hypertensives, histamine receptor antagonists); lifestyle (tobacco, alcohol use); diseases (diabetes, cardiovascular conditions, prostate cancer); prostatectomy, and spinal cord injuries. The market opportunity for ED medical treatments continues to grow, with U.S. sales exceeding $2.9 billion in 2012[2]. About one half of men being treated with currently available PDE5 inhibitors are dissatisfied with the results of that treatment and tend to switch among the products in pursuit of better efficacy or less side effects[3]. [1] Andre B. Prevalence and Incidence of Androgen Deficiency in Middle-Aged and Older Men: Estimates from The Massachusetts Male Ageing Study. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(12):5920-5926. [2] US TRx revenues per Symphony Health [3] Impact CR Consumer Segmentation, Feb. 2013; Qualitative Market Interviews (n= 722); HCP Research, Primary Interviews, Life Science Strategy Group LLC n= 64, June 2010. [URL]http://online.wsj.com/article/PR-CO-20131011-905164.html[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Stendra: Auxilium Gets The Rights for New ED pill
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top